临床医学ASCO大肠癌辅助化疗进展2003年ppt课件.pptVIP

MOSAIC: Conclusions – 1 FOLFOX4 is safe in adjuvant colon cancer All cause mortality under treatment 0.5% in both arms 2% febrile neutropenia Limited GI toxicity and alopecia Gr 3 sensory neuropathy: - observed in 12% of patients - only 1% at one year follow-up MOSAIC: Conclusions – 2 FOLFOX4 is the first combination to demonstrate superiority over 5FU/LV in adjuvant colon cancer Positive trial for the primary end point 3-year Disease Free Survival: 78% vs 73%, (p0.01) Reduction in the risk of recurrence by 23% Benefit of FOLFOX4 observed in all patient subsets Main steps in adjuvan